Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 11/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18016317 | 1.00 | KCNH2 (1.00) | KCNH2CHRNA7CHRNB2CHRNA4HRH3 | |
| SCHEMBL927738 | 1.00 | KCNH2 (1.00) | KCNH2CHRNA7CHRNB2CHRNA4HRH3 | |
| SCHEMBL927736 | 1.00 | KCNH2 (1.00) | KCNH2CHRNA7CHRNB2CHRNA4HRH3 | |
| SCHEMBL3182060 | 1.00 | KCNH2 (1.00) | KCNH2CHRNA7CHRNB2CHRNA4HRH3 | |
| SCHEMBL927571 | 0.88 | KCNH2 (0.78) | KCNH2CHRNA7CHRNB2CHRNA4LRRK2 | |
| SCHEMBL1790913 | 0.88 | KCNH2 (0.77) | KCNH2CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL1795253 | 0.88 | KCNH2 (0.77) | KCNH2CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL19488946 | 0.86 | KCNH2 (0.76) | KCNH2CHRNA7CHRNB2CHRNA4HTR3A | |
| SCHEMBL4114880 | 0.83 | KCNH2 (0.70) | KCNH2CHRNA7HRH3LRRK2 | |
| SCHEMBL4113432 | 0.83 | KCNH2 (0.70) | KCNH2CHRNA7HRH3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352107-A1 | ALPHA7 NEURONAL NICOTINIC RECEPTOR LIGAND AND ANTIPSYCHOTIC COMPOSITIONS | ABBVIE INC. | 2015-12-10 | — | — | US | claimed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | claimed |
| US-20060211686-A1 | Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | claimed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| EP-2931315-B1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-20080318941-A1 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20060211686-A1 | Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | KCNH2 2953/4885CHRNA7 1/4885CHRNB2 9/4885 |
| US-20060211686-A1 | Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions | CHRNA7, CHRNA5, CHRNA6 | KCNH2 334/4885CHRNA7 1/4885CHRNB2 10/4885 |
| US-20080318941-A1 | 4' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR3B | KCNH2 837/4885CHRNA7 148/4885CHRNB2 192/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | KCNH2 2839/4885CHRNA7 1/4885CHRNB2 9/4885 |
| US-20080200471-A1 | 6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR1B, HTR1A | KCNH2 1646/4885CHRNA7 204/4885CHRNB2 277/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | KCNH2 340/4885CHRNA7 1/4885CHRNB2 7/4885 |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | HTR6, HTR3B, HTR1B | KCNH2 803/4885CHRNA7 167/4885CHRNB2 210/4885 |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | KCNH2 2839/4885CHRNA7 1/4885CHRNB2 9/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | KCNH2 978/4885CHRNA7 1/4885CHRNB2 14/4885 |
| US-20150352107-A1 | ALPHA7 NEURONAL NICOTINIC RECEPTOR LIGAND AND ANTIPSYCHOTIC COMPOSITIONS | CHRNA7, CHRNA5, CHRNA6 | KCNH2 334/4885CHRNA7 1/4885CHRNB2 10/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | KCNH2 1554/4885CHRNA7 5/4885CHRNB2 12/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | KCNH2 2953/4885CHRNA7 1/4885CHRNB2 9/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | KCNH2 765/4885CHRNA7 1/4885CHRNB2 6/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | KCNH2 978/4885CHRNA7 1/4885CHRNB2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.